Dr. Deitcher is an innovative business leader who has more than 25 years of life science product development experience including cellular therapeutics, biologics, small molecules, and diagnostics. He was President, CEO and Board Member at Talon Therapeutics, a specialty biopharmaceutical company focused on novel cancer drug delivery. At Talon, his team advanced its lead compound, Marqibo®, from IND to FDA accelerated approval to treat leukemia and positioned the company for sale to Spectrum Pharmaceuticals. He previously served as Vice President and Chief Medical Scientist at Nuvelo. He was formerly the Chief of Hematology and Director of Thrombosis and Vascular Medicine Research at The Cleveland Clinic and held leadership positions at The University of Tennessee Health Science Center and St. Jude Children’s Research Hospital.
He received his B.S. and M.D. in the Honors Program in Medical Education at Northwestern University. He is a member of several corporate and university advisory boards and has authored 225 publications in medical and scientific journals.
Dr. Engleman is a Professor of Pathology and Medicine at Stanford University School of Medicine, where he oversees the Stanford Blood Center. His research has primarily focused on the interactions between cancer and the immune system. A former editor of numerous scientific journals and the inventor of multiple patented technologies, Dr. Engleman has authored more than 280 publications in medical and scientific journals and has trained more than 200 graduate students and postdoctoral fellows. He is a co-founder of Vivo Capital, LLC, and a scientific founder of a number of biopharmaceutical companies including Dendreon.
Dr. Engleman received his A.B. from Harvard University and his M.D. from Columbia University School of Medicine.
Dr. Kung is a founding member of Vivo Capital, LLC, a healthcare and biotechnology venture capital management firm headquartered in Palo Alto, California and 35 year veteran of the biotechnology industry. Dr. Kung started his career in the biotechnology industry when he joined Cetus Corporation. He later co-founded Cetus Immune Corporation, which was acquired by its parent company. In 1984 he co-founded Genelabs Technologies, Inc., where he served as Chairman and CEO until 1995.
Dr. Kung received his B.S. in chemistry from the National Tsing Hua University in Taiwan and his Ph.D. in molecular biology and M.B.A. from the University of California, Berkeley. Dr. Kung currently serves on the board of directors of a number of emerging healthcare and biotechnology companies.
Prior to joining WuXi Healthcare Ventures, Dr. Li focused his effort on healthcare and life science investment opportunities at Fidelity Biosciences, Fidelity Growth Partner Asia, and Baird Venture Partners. He also led drug discovery projects and technology licensing due diligence at Vertex Pharmaceuticals, an biotech company in Boston, MA. During his scientific career, Wei first-authored numerous scientific publications in journals including Science, Proceedings of the National Academy of Sciences, and Journal of Biological Chemistry.
Wei received a B.S., with distinction, in Chemical Physics from University of Science and Technology of China, a Ph.D. in Biochemistry and Mammalian Genetics from Harvard University, and an MBA from the Kellogg School of Management at Northwestern University, where he was elected Beta Gamma Sigma, with a concentration in Finance, Accounting and Marketing.
Dr. Liu started his career in the biotechnology industry in 1982 when he joined Cetus Corporation. He subsequently co-founded and served as president of General Biologicals Corporation a public immunodiagnostics company located in Taiwan where he was also a founding Board Member of the Development Center for Biotechnology. Dr. Liu later founded and served as President of Pepgen Corporation, which was focused on biotherapeutics for autoimmune and viral diseases.
Dr. Liu received his B.S. from National Taiwan Normal University and his Ph.D. from University of Wisconsin-Madison. Dr. Liu completed his postdoctoral research at Yale University and at the University of California-Berkeley.
Dr. Strober is Professor of Medicine at Stanford University School of Medicine and former Chief of the Division of Immunology and Rheumatology. He has been President of the Clinical Immunology Society, Chairman of the Board of the La Jolla Institute for Allergy and Immunology and was a scientific founder of Dendreon Corporation. Dr. Strober's research has focused on the immune cell interactions that prevent rejection of organ transplants in the absence of immunosuppressive drugs as well as cell interactions that prevent graft versus host disease and retain graft anti-tumor activity after hematopoietic cell transplantation. Dr. Strober has published over 300 peer-reviewed articles in scientific journals, is the inventor of multiple patented technologies, and has served on editorial boards of immunology journals
He received his B.A. from Columbia University and his M.D. from Harvard University.